An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity.

Anne Patsouris; Olivier Tredan; Loic Campion; Anthony Goncalves; Monica Arnedos; Marie Paule Sablin; Pascal Jézéquel; Marta Jimenez; Veronica Pezzella; Ivan Bieche; Celine Callens; Andrea Loehr; Daniel Nenciu; Cecile Vicier; Fabrice Andre

doi:10.1200/jco.2018.36.15_suppl.tps1112

An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.tps1112 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. TPS1112-TPS1112 ◽

Cited By ~ 1

Author(s):

Anne Patsouris ◽

Olivier Tredan ◽

Loic Campion ◽

Anthony Goncalves ◽

Monica Arnedos ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cancer Patients ◽

Loss Of Heterozygosity ◽

Phase Ii Study ◽

Parp Inhibitor ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Open Label ◽

Open Label Phase

Download Full-text

1876 A phase II study of metronomic oral chemotherapy for metastatic breast cancer patients: Safety and efficacy results of vinorelbine, cyclophosphamide plus capecitabine (VEX) combination

European Journal of Cancer ◽

10.1016/s0959-8049(16)30826-7 ◽

2015 ◽

Vol 51 ◽

pp. S291-S292 ◽

Cited By ~ 6

Author(s):

E. Montagna ◽

A. Lai ◽

A. Palazzo ◽

V. Bagnardi ◽

G. Cancello ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Oral Chemotherapy ◽

Breast Cancer Patients ◽

Safety And Efficacy

Download Full-text

5062 Fulvestrant in heavily pre-treated ER-positive post-menopausal metastatic breast cancer patients: final update of a phase II study

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)70954-1 ◽

2009 ◽

Vol 7 (2) ◽

pp. 279

Author(s):

R. Ratti ◽

Z. Coccorullo ◽

D. Guarneri ◽

G. Addamo ◽

G. Colloca ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Er Positive ◽

Post Menopausal

Download Full-text

P5-19-02: Comparison of the Incidence of Peripheral Neuropathy with Eribulin Mesylate Versus Ixabepilone in Metastatic Breast Cancer Patients: A Randomized Phase II Study.

10.1158/0008-5472.sabcs11-p5-19-02 ◽

2011 ◽

Cited By ~ 1

Author(s):

L Vahdat ◽

P Gopalakrishna ◽

AA Garcia ◽

C Vogel ◽

C Pellegrino ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Peripheral Neuropathy ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Eribulin Mesylate ◽

Randomized Phase Ii

Download Full-text

A randomized, open label, phase II study of prophylactic octreotide (OCT) to prevent/reduce the frequency and severity of diarrhea in patients (pts) receiving lapatinib (LAP) with capecitabine (CAP) for the treatment of metastatic breast cancer (mBC)

Annals of Oncology ◽

10.1093/annonc/mdy272.309 ◽

2018 ◽

Vol 29 ◽

pp. viii102

Author(s):

P. Krivorotko ◽

B. Karaszewska ◽

S. Chan ◽

M. Wieczorek-Rutkowska ◽

T. Sarosiek ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Open Label ◽

Open Label Phase

Download Full-text

Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-03-0463 ◽

2004 ◽

Vol 10 (12) ◽

pp. 4062-4067 ◽

Cited By ~ 47

Author(s):

Chau T. Dang ◽

Andrew J. Dannenberg ◽

Kotha Subbaramaiah ◽

Maura N. Dickler ◽

Mark M. Moasser ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Breast Cancer Patients

Download Full-text

A Phase II study to assess the safety and efficacy of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER positive locally advanced or metastatic breast cancer patients (IRIS) – Trial Results.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.549 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 549-549 ◽

Cited By ~ 2

Author(s):

Carlo Palmieri ◽

Robert C. Stein ◽

Xinxue Liu ◽

Emma Hudson ◽

Sadie Reed ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cancer Patients ◽

Phase Ii Study ◽

Locally Advanced ◽

Metastatic Breast ◽

Steroid Sulfatase ◽

Breast Cancer Patients ◽

Safety And Efficacy ◽

Er Positive

Download Full-text

A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance

Breast Cancer ◽

10.1007/s12282-012-0344-3 ◽

2012 ◽

Vol 21 (1) ◽

pp. 20-27 ◽

Cited By ~ 10

Author(s):

Masakazu Toi ◽

Toshiaki Saeki ◽

Hiroji Iwata ◽

Kenichi Inoue ◽

Yutaka Tokuda ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Tyrosine Kinase Inhibitor ◽

Cancer Patients ◽

Kinase Inhibitor ◽

Phase Ii Study ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Anthracycline Resistance ◽

Multicenter Phase

Download Full-text

Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: A phase II study

Annals of Oncology ◽

10.1023/a:1008334227668 ◽

2001 ◽

Vol 12 (1) ◽

pp. 95-100 ◽

Cited By ~ 13

Author(s):

F. Nolè ◽

E. Munzone ◽

M. Mandalà ◽

C. Catania ◽

L. Orlando ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Continuous Infusion ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Breast Cancer Patients

Download Full-text

A phase II study of gemcitabine plus capecitabine (GC) in heavily pre-treated metastatic breast cancer patients. The Swedish GC Breast Cancer Study Group

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(08)70736-5 ◽

2008 ◽

Vol 6 (7) ◽

pp. 175-176

Author(s):

A. Malmstrom ◽

J. Hansen ◽

L. Malmberg ◽

L. Carlsson ◽

J.H. Svensson ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Study Group ◽

Breast Cancer Patients ◽

Cancer Study Group ◽

Breast Cancer Study

Download Full-text

Clinical activity of cisplatin and prolonged oral administration of etoposide in previously treated, anthracycline-resistant, metastatic breast cancer patients: A phase II study

Medical and Pediatric Oncology ◽

10.1002/(sici)1096-911x(200001)34:1<10::aid-mpo2>3.0.co;2-a ◽

2000 ◽

Vol 34 (1) ◽

pp. 10-13 ◽

Cited By ~ 4

Author(s):

Getta Fried ◽

Moshe E. Stein ◽

Nissim Haim

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Oral Administration ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Clinical Activity ◽

Breast Cancer Patients ◽

Previously Treated

Download Full-text